A two stage randomized, open label, parallel group, phase III, multicenter, 7 month study to assess the efficacy and safety of Symbicort [budesonide/formoterol] pMDI [pressurised metered dose inhalers] adminstered either as fixed or as an adjustable regimen versus a fixed regimen of advair [salmeterol/fluticasone propionate] in subjects 12 yrs of age and older with asthma.
Phase of Trial: Phase III
Latest Information Update: 01 Jan 2010
At a glance
- Drugs Budesonide/formoterol; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
- 17 Apr 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History